Exact Sciences Announces Preliminary Fourth Quarter 2023 Results
Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits next-generation Cologuard® to FDA
Announces Chief Financial Officer succession plan
Related news for (EXAS)
- Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
- Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
- Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
- Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
- Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy